Tumor Exome Sequencing and Copy Number Alterations Reveal Potential Predictors of Intrinsic Resistance to Multi-Targeted Tyrosine Kinase Inhibitors
Nancy K. Gillis,Daniel M. Rotroff,Tania E. Mesa,Jiqiang Yao,Zhihua Chen,Michael A. Carulli,Sean J. Yoder,Christine M. Walko,Jamie K. Teer,Howard L. McLeod
DOI: https://doi.org/10.18632/oncotarget.22914
2017-01-01
Oncotarget
Abstract:Multi-targeted tyrosine kinase inhibitors (TKIs) have broad efficacy and similar FDA-approved indications, suggesting shared molecular drug targets across cancer types. Irrespective of tumor type, 20-30% of patients treated with multi-targeted TKIs demonstrate intrinsic resistance, with progressive disease as a best response. We conducted a retrospective cohort study to identify tumor (somatic) point mutations, insertion/deletions, and copy number alterations (CNA) associated with intrinsic resistance to multi-targeted TKIs. Using a candidate gene approach (n=243), tumor next-generation sequencing and CNA data was associated with resistant and non-resistant outcomes. Resistant individuals (n=11) more commonly harbored somatic point mutations in NTRK1, KDR, TGFBR2, and PTPN11 and CNA in CDK4, CDKN2B, and ERBB2 compared to non-resistant (n=26, p<0.01). Using a random forest classification model for variable reduction and a decision tree classification model, we were able to differentiate intrinsically resistant from non-resistant patients. CNA in CDK4 and CDKN2B were the most important analytical features, implicating the cyclin D pathway as a potentially important factor in resistance to multi-targeted TKIs. Replication of these results in a larger, independent patient cohort has potential to inform personalized prescribing of these widely utilized agents.